Purchase this article with an account.
M. Francesca Cordeiro, Jennifer A. Gay, Peng T. Khaw; Human Anti-Transforming Growth Factor-β2 Antibody: A New Glaucoma Anti-Scarring Agent. Invest. Ophthalmol. Vis. Sci. 1999;40(10):2225-2234.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. Currently available anti-scarring regimens for glaucoma filtration
surgery have potentially blinding complications and thus the need for
alternative and safer agents. The effects of a new antibody to
transforming growth factor (TGF)-β2 on in vitro and in vivo
conjunctival scarring and after glaucoma filtration surgery were
methods. The activity of a novel recombinant monoclonal neutralizing antibody
(mAb) to human TGF-2 (rhAnti-TGF-β2 mAb) was studied in conjunctival
fibroblast-mediated proliferation, migration, and collagen contraction.
Its safety in subconjunctival administration was assessed in vivo, and,
in a rabbit model of glaucoma filtration surgery, its effects on
conjunctival scarring and filtration surgery outcome were investigated.
results. The rhAnti-TGF-β2 mAb effectively inhibited TGF-β2–mediated
conjunctival scarring activity in vitro, at 50% inhibitory
concentrations (IC50) of less than 1 nM. It significantly
improved glaucoma filtration surgery outcome in an animal model of
aggressive conjunctival scarring compared with control
(P = 0.0291) and was clinically safe, nontoxic, and
well tolerated after subconjunctival administration.
conclusions. Subconjunctival rhAnti-TGF-β2 mAb treatment significantly
affects surgical outcome and effectively reduces conjunctival scarring
both in vitro and in vivo. It appears safe for subconjunctival
administration and when compared with mitomycin-C treatment
histologically, much less destructive to local tissue. rhAnti-TGF-β2
mAb may have potential as a new anti-scarring agent for use in glaucoma
This PDF is available to Subscribers Only